Ken Griffin Intercept Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	SELL	$9.99 - $18.71 $132,867 - $248,843	-13,300 Reduced 7.15%	172,600 $3.2 Million
Q2 2023 Aug 14, 2023	BUY	$9.17 - $19.29 $679,497 - $1.43 Million	74,100 Added 66.28%	185,900 $2.06 Million
Q1 2023 May 15, 2023	SELL	$12.53 - $21.71 $692,909 - $1.2 Million	-55,300 Reduced 33.09%	111,800 $1.5 Million
Q4 2022 Feb 14, 2023	SELL	$11.61 - $16.11 $1.96 Million - $2.72 Million	-169,000 Reduced 50.28%	167,100 $2.07 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $2.23 Million - $3.59 Million	182,400 Added 118.67%	336,100 $4.69 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.